Nortech Systems Inc. (NSYS) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Nortech Systems Inc. is a global EMS contract manufacturer serving the Medical, Aerospace & Defense, and Industrial markets. This report covers the quarterly period ended September 30, 2024. The company operates facilities in Minnesota, Mexico, and China. In May 2024, management announced the closure of its Blue Earth, Minnesota facility, with operations consolidating to the Bemidji facility by the end of 2024.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Sales | $31.4M | $33.4M | $99.5M | $103.3M |
| Gross Profit | $3.8M | $5.3M | $13.9M | $16.3M |
| Gross Margin | 12.2% | 15.9% | 14.0% | 15.8% |
| Operating Income (Loss) | $(0.5M) | $1.1M | $1.0M | $3.3M |
| Net Income (Loss) | $(0.7M) | $1.2M | $0.2M | $2.5M |
| Cash from Operations (YTD) | $(3.0M) | $2.2M | $(3.0M) | $2.2M |
| Line of Credit Outstanding | $9.6M | $5.8M | $9.6M | $5.8M |
| Cash & Equivalents | $1.2M | $1.1M | $1.2M | $1.1M |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 5.9% in Q3 and 3.6% YTD compared to 2023. The Industrial segment saw a significant 19.2% drop in Q3 due to customer inventory reduction and delayed launches. The Medical segment declined 9.7% YTD due to inventory rebalancing and timing of product launches.
- Margin Compression: Gross margin contracted to 12.2% in Q3 (down 370 basis points) and 14.0% YTD (down 180 basis points), driven by lower sales volume and reduced operating leverage.
- Profitability Shift: The company reported an operating loss of $0.5M in Q3, compared to an operating income of $1.1M in the prior year. This was driven by lower gross profit and the inclusion of restructuring charges.
- Restructuring Costs: The company incurred $0.2M in restructuring charges in Q3 and $0.3M YTD related to the closure of the Blue Earth facility. Total expected cash restructuring costs for 2024 are approximately $0.8M.
- Backlog Reduction: Total order backlog decreased 31.8% year-over-year to $69.8M, attributed to customers returning to pre-pandemic ordering practices and reduced visibility due to inventory rebalancing.
Guidance, Outlook, and Risks
- Outlook: Management expects reduced revenue visibility in the coming quarters as customers rebalance inventories. The company anticipates completing the facility consolidation in Q4 2024.
- Liquidity: The company maintains a $15.0M Senior Secured Revolving Line of Credit with Bank of America. As of September 30, 2024, $9.6M was outstanding with $5.5M available. The company met all financial covenants, though it received a waiver in August 2024 for a temporary covenant breach regarding operating expense contributions to Mexican operations.
- Risks: Key risks include supply chain disruptions, loss of major customers (one customer represented 28% of Q3 sales), currency exchange volatility, and the financial impact of the facility transition.
- Unusual Items: A full allowance was recorded against $85k in receivables from a related party (Abilitech Medical) that has ceased operations. Additionally, the company is involved in a joint grant application with Marpe Technologies, a related party.
Investor Verification Checklist
- Facility Transition: Verify the timeline and cost impact of moving operations from Blue Earth to Bemidji, specifically the $0.8M restructuring cost estimate.
- Customer Concentration: Assess the risk associated with the top customer representing 28% of Q3 sales and 22% of gross accounts receivable.
- Backlog Quality: Review the composition of the $69.8M backlog to understand the mix of firm orders versus potential cancellations given the 31.8% year-over-year decline.
- Cash Flow Sustainability: Monitor the negative operating cash flow of $3.0M YTD and the reliance on the line of credit to fund working capital needs.
- Related Party Transactions: Confirm the status of the $85k receivable from Abilitech and the progress of the joint grant with Marpe Technologies.